This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bristol-Myers Squibb Company
Drug Names(s): R1645
Description: KOS-1584 (9,10-didehydroepothilone D) is a polyketide that inhibits cancer cell growth in vitro by a mechanism similar to paclitaxel. Preclinical models have demonstrated antitumor efficacy against paclitaxel-resistant tumors.
Deal Structure: Kosan and Roche established a global development and commercialization agreement for epothilones to treat cancer in September 2002. Under the terms of the agreement, Roche will fund development activities and have the worldwide exclusive rights to market and sell R1645 if approved. Kosan will co-develop and have the right to co-promote the product in the U.S. Kosan is eligible to receive additional payments upon achievement of certain clinical, regulatory and commercial milestones. Kosan will receive royalties on sales and may further increase such royalties through a buy-in option at a later stage of clinical development.
In October 2007, Kosan Biosciences announced that Roche and Kosan are concluding their epothilone development and commercialization collaboration. The collaborative research, development and commercialization agreement will terminate after a transition period, following which Kosan will reacquire worldwide rights to its epothilone program and have full control...See full deal structure in Biomedtracker
Pink Sheet Roche Backs Out Of Kosan Epothilone Deal
Pink Sheet Kosan drug fails prostate cancer trial
Additional information available to subscribers only: